Poster Abstract Session:
67. Resistance Mechanisms: Gram-Negative
Thursday, October 4, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Adult ID, Investigative ID


Presentations:
695
Regional and Longitudinal Mapping of Escherichia coli Antibiotic Susceptibility
Laurel Legenza, PharmD, MS; Susanne Barnett, PharmD; Jim Lacy, MS; Natalee Desotell, MS; Andrea Eibergen, BS Candidiate; Warren Rose, PharmD, MPH
696
Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
Akinobu Ito, Ph.D; Toru Nishikawa, -; Ryuta Ishii, M.S.; Miho Kuroiwa, Ph.D; Yoshino Ishioka, M.S.; Naoko Kurihara, M.S.; Ikue Sakikawa, -; Takeshi Ota, Ph.D; Masatomo Rokushima, Ph.D; Masakatsu Tsuji, Ph.D; Takafumi Sato, Ph.D; Yoshinori Yamano, Ph.D
698
Nacubactam Inhibits Class A β-lactamases
Melissa D. Barnes, PhD; Caryn E. Good, MA/MPH; Saralee Bajaksouzian, MS; Magdalena A. Taracila, MS; David Van Duin, MD, PhD; Barry N. Kreiswirth, PhD; Michael R. Jacobs, MD/PhD; Krisztina M. Papp-Wallace, PhD; Robert A. Bonomo, MD
699
Relationship between Klebsiella pneumoniae Antimicrobial Resistance and Biofilm Formation
Jaclyn Cusumano, PharmD; Kathryn Daffinee, BS; Megan Luther, Pharm.D.; Vrishali Lopes, MS; Aisling Caffrey, PhD, MS; Kerry LaPlante, Pharm.D., FCCP, FIDSA
700
Identification and Whole Genome Sequencing (WGS) of meropenem-vaborbactam (MV) resistant Klebsiella pneumoniae (MVRKP) among patients without prior exposure to MV: Collateral damage
Mohamad Yasmin, MD; Liang Chen, PhD; Steven H. Marshall, MS; Barry N. Kreiswirth, PhD; Federico Perez, MD, MS; Robert A. Bonomo, MD
701
Rapid detection of antimicrobial resistance determinants with the BioFire® System
Stefanie Marxreiter, MSc; Eric Lo, BS; Cody Oswald, BS; Aubrie Hopper, MLS, ASCP; Becki Barr, MLS, ASCP; Judy A. Daly, PhD; Kimberly E. Hanson, MD, MHS; Christine C. Ginocchio, PhD MT; Robert Crisp, PhD; Andrew Hemmert, PhD
Posters
  • AMR Panel IDWeek2018.pdf (1.6 MB)
  • 702
    Zinc Blockade of SOS Response Inhibits Horizontal Transfer of Antibiotic Resistance Genes in Enteric Bacteria
    John Crane, MD PhD, FIDSA; Mark Sutton, PhD; Muhammad Cheema, MBBS; Michael Olyer, High School Diploma
    703
    Mechanisms of High-Level Ceftolozane/Tazobactam (CT) Resistance against Pseudomonas aeruginosa and Synergy between CT and tobramycin (TOB)
    Wonhee So, PharmD; James Shurko, PharmD; Ralph Galega, MS; Rod E. Quilitz, PharmD; John Greene, MD, FACP; Grace C. Lee, PharmD, PhD
    705
    Four Superbugs isolated from a Single Patient in the United States: E. coli (EC) and K. pneumoniae (KP) harboring NDM-5, P. aeruginosa (PA) harboring NDM-1 and Candida auris
    Ayesha Khan, B.Sc.; Blake Hanson, PhD; An Dinh, BS; Audrey Wanger, PhD; Luis Ostrosky-Zeichner, MD, FIDSA, FSHEA; William Miller, MD; Cesar Arias, MD, PhD, FIDSA
    706
    Ceftazidime-avibactam (CZA) and meropenem (MER) are Synergistic and Bactericidal against Genetically-diverse KPC-producing Klebsiella pneumoniae (Kp)
    Chelsea Jones, BA; Ellen Kline, MS; Kristin Morder, BA; Cornelius J. Clancy, M.D.; M. Hong Nguyen, MD; Ryan K. Shields, PharmD
    707
    Clarifying the Role of CrrB in Polymxyin Resistant Klebsiella pneumoniae Clinical Isolates Utilizing a Novel CRISPR-Cas9 System
    Thomas McConville, MD; Marla Giddins, B.A.; Nenad Macesic, MBBS; Anne-Catrin Uhlemann, MD, PhD
    708
    Incidence and Relatedness of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Infections in Previously Colonized or Infected Patients
    Sarah Si Lin Tang, BSc (Pharm) (Hons); Jocelyn Teo, Masters in Infectious Diseases; Piotr Chlebicki, MBBS; Andrea L. Kwa, PharmD
    Posters
  • CRE poster.pdf (723.4 kB)
  • 709
    Activity of Key β-Lactam Agents against Gram-Negative Bacilli from ICU Patients with Lower Respiratory Tract Infections – SMART United States 2015-2017
    Sibylle Lob, Ph.D; Krystyna Kazmierczak, Ph.D; Daryl Hoban, Ph.D; Meredith Hackel, Ph.D; Katherine Young, MS; Mary Motyl, PhD; Dan Sahm, PhD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.